The Evolving Landscape of the Molecular Epidemiology of Malignant Pleural Mesothelioma.
genetics
mesothelioma
molecular epidemiology
personalized medicine
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
03 Mar 2021
03 Mar 2021
Historique:
received:
03
01
2021
revised:
15
02
2021
accepted:
24
02
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy that most commonly affects the pleural lining of the lungs. It has a strong association with exposure to biopersistent fibers, mainly asbestos (80% of cases) and-in specific geographic regions-erionite, zeolites, ophiolites, and fluoro-edenite. Individuals with a chronic exposure to asbestos generally have a long latency with no or few symptoms. Then, when patients do become symptomatic, they present with advanced disease and a worse overall survival (about 13/15 months). The fibers from industrial production not only pose a substantial risk to workers, but also to their relatives and to the surrounding community. Modern targeted therapies that have shown benefit in other human tumors have thus far failed in MPM. Overall, MPM has been listed as orphan disease by the European Union. However, molecular high-throughput profiling is currently unveiling novel biomarkers and actionable targets. We here discuss the natural evolution, mainly focusing on the novel concept of molecular epidemiology. The application of innovative endpoints, quantification of genetic damages, and definition of genetic susceptibility are reviewed, with the ultimate goal to point out new tools for screening of exposed subject and for designing more efficient diagnostic and therapeutic strategies.
Identifiants
pubmed: 33802313
pii: jcm10051034
doi: 10.3390/jcm10051034
pmc: PMC7959144
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Cancer Res. 2009 Jan 1;69(1):227-34
pubmed: 19118007
Biomed Res Int. 2015;2015:635748
pubmed: 25756049
Lancet Oncol. 2015 Apr;16(4):447-56
pubmed: 25800891
Curr Opin Oncol. 2021 Jan;33(1):80-86
pubmed: 33186182
Adv Exp Med Biol. 2013;754:137-48
pubmed: 22956499
Science. 1990 Nov 30;250(4985):1233-8
pubmed: 1978757
Nat Med. 2015 Nov;21(11):1344-9
pubmed: 26437366
Eur Respir Rev. 2015 Mar;24(135):115-31
pubmed: 25726562
Cancer. 2007 Apr 15;109(8):1454-61
pubmed: 17348013
Nat Cell Biol. 2018 Oct;20(10):1181-1192
pubmed: 30202049
Cancer Gene Ther. 2013 Mar;20(3):150-6
pubmed: 23392201
Cancer Chemother Pharmacol. 2017 Oct;80(4):861-867
pubmed: 28756516
Am J Ind Med. 2017 May;60(5):432-436
pubmed: 28244606
J Mol Diagn. 2010 Nov;12(6):771-9
pubmed: 20864637
Eur J Cancer Prev. 1997 Apr;6(2):162-6
pubmed: 9237066
Am J Respir Cell Mol Biol. 2010 Mar;42(3):312-9
pubmed: 19502386
BMC Cancer. 2013 Apr 24;13:205
pubmed: 23617783
Cancer Res. 2016 Jan 15;76(2):206-15
pubmed: 26719535
J Biol Chem. 2010 Jul 23;285(30):22809-17
pubmed: 20463022
Cancers (Basel). 2020 May 07;12(5):
pubmed: 32392897
Curr Cancer Drug Targets. 2016;16(2):101-9
pubmed: 26517537
Dis Markers. 2019 Feb 12;2019:4183157
pubmed: 30891101
J Thorac Oncol. 2014 Nov;9(11):1662-8
pubmed: 25436799
J Thorac Oncol. 2018 Oct;13(10):1588-1594
pubmed: 30056163
Br J Cancer. 2020 Jan;122(1):52-61
pubmed: 31819191
Curr Treat Options Oncol. 2011 Jun;12(2):173-80
pubmed: 21519819
Proc Natl Acad Sci U S A. 2020 Oct 13;117(41):25543-25552
pubmed: 32999071
Med Oncol. 2014 Dec;31(12):303
pubmed: 25358615
Ther Adv Med Oncol. 2020 Nov 12;12:1758835920971421
pubmed: 33240401
Oncotarget. 2015 May 30;6(15):13757-71
pubmed: 25970771
J Thorac Oncol. 2015 Apr;10(4):565-76
pubmed: 25658628
Am J Surg Pathol. 2020 Feb;44(2):288-292
pubmed: 31567203
Multidiscip Respir Med. 2018 Aug 2;13:27
pubmed: 30123503
J Cell Biochem. 2019 Mar;120(3):3203-3211
pubmed: 30362153
Occup Environ Med. 1994 Dec;51(12):804-11
pubmed: 7849863
Cancer Res. 2014 Aug 15;74(16):4388-97
pubmed: 24928783
Epigenomics. 2016 Aug;8(8):1079-85
pubmed: 27185582
Oncogene. 2016 Feb 4;35(5):537-48
pubmed: 25893302
J Natl Cancer Inst. 2006 Mar 15;98(6):414-7
pubmed: 16537834
PLoS One. 2011 Apr 01;6(4):e18232
pubmed: 21483773
Nat Med. 2003 Nov;9(11):1408-12
pubmed: 14566335
Int J Cancer. 2010 Oct 15;127(8):1948-57
pubmed: 20104519
Annu Rev Public Health. 1984;5:1-52
pubmed: 6232928
Clin Chem. 1995 Dec;41(12 Pt 2):1800-3
pubmed: 7497635
Exp Mol Pathol. 2014 Dec;97(3):375-85
pubmed: 25236577
Cancers (Basel). 2020 Oct 13;12(10):
pubmed: 33065998
J Med Genet. 2010 Jun;47(6):421-8
pubmed: 20522432
Br J Cancer. 1989 Nov;60(5):708-11
pubmed: 2803947
Carcinogenesis. 2008 Jul;29(7):1306-11
pubmed: 18477647
J Thorac Oncol. 2011 May;6(5):844-51
pubmed: 21358347
Toxicol Pathol. 2000 Mar-Apr;28(2):253-66
pubmed: 10805143
Transl Lung Cancer Res. 2017 Jun;6(3):350-365
pubmed: 28713680
Antioxid Redox Signal. 2014 Nov 20;21(15):2109-25
pubmed: 24444362
Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):285-90
pubmed: 24347639
Front Oncol. 2020 Sep 23;10:579464
pubmed: 33072611
Mol Aspects Med. 1998 Dec;19(6):359-432
pubmed: 10385877
Transl Oncol. 2018 Apr;11(2):268-274
pubmed: 29413759
Nat Genet. 2016 Apr;48(4):407-16
pubmed: 26928227
Transl Lung Cancer Res. 2020 Feb;9(Suppl 1):S60-S66
pubmed: 32206571
Sci Rep. 2019 Aug 12;9(1):11688
pubmed: 31406207
Ann Diagn Pathol. 2003 Oct;7(5):321-32
pubmed: 14571437
Curr Opin Cell Biol. 2019 Dec;61:110-116
pubmed: 31476530
Ann Epidemiol. 2015 Mar;25(3):147-54
pubmed: 25721747
PLoS One. 2015 Aug 11;10(8):e0135331
pubmed: 26262875
J Cancer Res Clin Oncol. 2009 Jan;135(1):15-27
pubmed: 18787841
Proc Natl Acad Sci U S A. 2010 Jul 13;107(28):12611-6
pubmed: 20616036
J Mol Diagn. 2014 Jul;16(4):418-30
pubmed: 24912849
Nat Genet. 2011 Aug 28;43(10):1022-5
pubmed: 21874000
BMC Cancer. 2018 Feb 7;18(1):158
pubmed: 29415665
Regul Toxicol Pharmacol. 2008 Oct;52(1 Suppl):S154-86
pubmed: 18396365
Am J Epidemiol. 1981 Mar;113(3):250-3
pubmed: 7468580
Front Mol Biosci. 2019 Oct 18;6:91
pubmed: 31750312
Pathology. 2013 Feb;45(2):116-26
pubmed: 23277170
J Chronic Dis. 1982;35(7):581-600
pubmed: 6282919
CA Cancer J Clin. 2005 Jan-Feb;55(1):45-54; quiz 57
pubmed: 15661686
Transl Lung Cancer Res. 2018 Feb;7(Suppl 1):S60-S61
pubmed: 29531907
Cancer Res. 2016 Jan 15;76(2):319-28
pubmed: 26554828
Genes Chromosomes Cancer. 2009 Jul;48(7):615-23
pubmed: 19396864
JAMA Netw Open. 2020 Oct 1;3(10):e2025109
pubmed: 33119110
EJNMMI Res. 2020 Jul 13;10(1):81
pubmed: 32661672
Biochem Biophys Res Commun. 2013 Oct 11;440(1):82-7
pubmed: 24041698
Acad Radiol. 2017 Oct;24(10):1277-1287
pubmed: 28434856
Biomark Med. 2018 Feb;12(2):129-139
pubmed: 29338319
JAMA. 2008 May 28;299(20):2423-36
pubmed: 18505952
Am J Public Health. 1996 May;86(5):678-83
pubmed: 8629719
Clin Epigenetics. 2019 May 16;11(1):81
pubmed: 31097014
Clin Epigenetics. 2018 Apr 23;10:59
pubmed: 29713393
Cancer. 1997 Jun 1;79(11):2237-42
pubmed: 9179072
Signal Transduct Target Ther. 2016 Jan 28;1:15004
pubmed: 29263891
J Biol Chem. 2009 Aug 14;284(33):22491-22499
pubmed: 19553700
Eur Rev Med Pharmacol Sci. 2019 Jul;23(13):5874-5883
pubmed: 31298338
BMC Cancer. 2015 Jan 15;15:8
pubmed: 25588929
BMC Cancer. 2015 May 08;15:374
pubmed: 25952930
Dis Markers. 2019 Jul 31;2019:8628612
pubmed: 31481984
Curr Opin Genet Dev. 2010 Jun;20(3):330-5
pubmed: 20359883
Clin Cancer Res. 2006 Oct 1;12(19):5777-85
pubmed: 17020984
Nat Genet. 2011 Aug 28;43(10):1018-21
pubmed: 21874003
Occup Environ Med. 2017 Nov;74(11):838-846
pubmed: 28935666
Radiol Oncol. 2020 Oct 21;54(4):429-436
pubmed: 33085641
Environ Health Perspect. 2006 Mar;114(3):A160-7
pubmed: 16507447
Nat Rev Drug Discov. 2006 Jan;5(1):37-50
pubmed: 16485345
Lung Cancer. 2020 Nov;149:1-4
pubmed: 32932212
Cancer Med. 2016 May;5(5):950-9
pubmed: 26860323
PLoS One. 2017 May 4;12(5):e0176680
pubmed: 28472171
Clin Genet. 2016 Mar;89(3):285-94
pubmed: 26096145
Cancer Res. 2010 Mar 1;70(5):1916-24
pubmed: 20160038
Cell Commun Signal. 2017 Mar 31;15(1):13
pubmed: 28359286
Cancer Genet. 2015 Oct;208(10):502-7
pubmed: 26364129
Nat Genet. 2011 Jun 05;43(7):668-72
pubmed: 21642991
Oncolytic Virother. 2015 Sep 10;4:133-40
pubmed: 27512676
Cancer Genet. 2013 May;206(5):206-10
pubmed: 23849051
Dis Markers. 2017;2017:5756102
pubmed: 28348451
Mutat Res. 2019 Jul - Sep;781:1-10
pubmed: 31416570
Epigenomics. 2016 Feb;8(2):271-83
pubmed: 26505319
Eur Radiol Exp. 2018 Nov 14;2(1):36
pubmed: 30426318
Cancer Res. 2009 Dec 1;69(23):9073-82
pubmed: 19887624
J Thorac Oncol. 2015 Mar;10(3):492-9
pubmed: 25514803
CA Cancer J Clin. 2019 Sep;69(5):402-429
pubmed: 31283845
Lab Invest. 2004 Aug;84(8):1013-23
pubmed: 15122306
Br J Ind Med. 1960 Oct;17:260-71
pubmed: 13782506
Nature. 2019 Aug;572(7769):402-406
pubmed: 31341276
Cancer Lett. 2016 Aug 10;378(2):120-30
pubmed: 27181379
Front Oncol. 2019 Nov 27;9:1318
pubmed: 31828040
Mol Ther. 2014 Nov;22(11):1949-59
pubmed: 25156126
Exp Biol Med (Maywood). 2018 Feb;243(3):213-221
pubmed: 29405771
J Cell Mol Med. 2012 Jan;16(1):8-21
pubmed: 21692980
J Cancer Res Clin Oncol. 1988;114(3):259-65
pubmed: 2454926
J Thorac Oncol. 2016 Oct;11(10):1615-26
pubmed: 27282309
PLoS One. 2012;7(1):e30221
pubmed: 22253921
JAMA Ophthalmol. 2015 Aug;133(8):881-7
pubmed: 25974357
Biochem Soc Trans. 2012 Apr;40(2):341-6
pubmed: 22435809
Acta Med Okayama. 2014;68(1):23-6
pubmed: 24553485
Am Soc Clin Oncol Educ Book. 2013;:81-90
pubmed: 23714463
Chem Res Toxicol. 2019 Nov 18;32(11):2153-2155
pubmed: 31509385
Front Oncol. 2018 Dec 21;8:650
pubmed: 30622932
Biointerphases. 2011 Jun;6(2):P1-17
pubmed: 21721837
Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):13618-23
pubmed: 21788493
Am J Ind Med. 1992;21(2):253-73
pubmed: 1536158
Cancer Sci. 2012 May;103(5):868-74
pubmed: 22321046
Dis Markers. 2017;2017:2536187
pubmed: 29386699
Oncogene. 2014 Nov 13;33(46):5319-31
pubmed: 24240684
Cancer Res. 2010 Jun 1;70(11):4297-309
pubmed: 20484030
J Thorac Oncol. 2017 Aug;12(8):1309-1319
pubmed: 28389374
Clin Epigenetics. 2018 Jun 18;10:79
pubmed: 29946373
Cancer Sci. 2003 Apr;94(4):321-7
pubmed: 12824898
Lancet Oncol. 2017 Oct;18(10):1386-1396
pubmed: 28870611